The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds

https://doi.org/10.1016/j.bmcl.2013.12.024Get rights and content

Abstract

Compounds 7, 8, and 9, derived from the novel scaffolds 3, 5, and 6, were synthesized and evaluated in vitro. The b,c  c,d shift of the E-phenyl ring resulted in a large decrease (ca. 20- to 1000-fold) in binding to the 5-HT2A, 5-HT2C and H2, receptors, and a modest decrease (ca. 10- to 20-fold) in binding to the 5-HT5A, D2, D5, and α1D, receptors. The b,c  d,e shift resulted in a large decrease in binding to the 5-HT1D, 5-HT2C, 5-HT6, and H1 receptors, a modest decrease in binding to 5-HT1A, 5-HT5A and D2, D5, α2B, and H2 receptors, and a large increase in affinity to the 5-HT3, 5-HT6, and σ1 receptors.

Section snippets

Acknowledgements

We thank University of North Carolina Psychoactive Drug Screening Program (PDSP) supported by NIMH for the receptor binding studies.

References and notes (33)

  • A. Dogrul et al.

    Eur. J. Pharmacol.

    (2012)
  • E. Amaya-Castellanos et al.

    Pharmacol., Biochem. Behav.

    (2011)
  • A. Ulugol et al.

    Pharmacol., Biochem. Behav.

    (2012)
  • A. Brenchat et al.

    Pain

    (2010)
  • N. Khorana et al.

    Bioorg. Med. Chem.

    (2003)
  • A.V. Ivachtchenko et al.

    Bioorg. Med. Chem. Lett.

    (2010)
  • J. Bonjoch et al.

    Bioorg. Med. Chem. Lett.

    (2009)
  • M.V. Nandakumar et al.

    Tetrahedron

    (2005)
  • J.M. Entrena et al.

    Pain

    (2009)
  • D.E. Nichols et al.

    Chem. Rev.

    (2008)
  • L. Bevilacqua et al.

    Nature

    (2010)
  • A.L. Auclair et al.

    J. Neurochem.

    (2010)
  • S. Doly et al.

    PLoS ONE

    (2009)
  • J. Brea et al.

    Curr. Top. Med. Chem.

    (2010)
  • S. Chaudhary et al.

    Int. Res. J. Pharm.

    (2010)
  • Rajagopalan, P. U.S. Patent 4,013,652,...
  • Cited by (19)

    • Recent developments on synthesis and biological activities of γ-carboline

      2018, European Journal of Medicinal Chemistry
      Citation Excerpt :

      The latest research on these receptors has clearly defined the key roles that 5-HT2B plays in psychostimulant addiction through the modulation of dopamine release in the reward/pleasure centers in the brain, 5-HT6 in cognition, and 5-HT7 in both nociceptive and neuropathic pain via the descending serotonergic pathway. In 2014, Rajagopalan's group reported two compounds (169 and 170) that are highly selective ligands having moderate affinities to 5-HT7 and 5-HT2B and which play critical roles in neuropathic pain and psychostimulant addiction (Fig. 22) [65]. In 1989, it was reported that treatment of schizophrenic patients with the 5-HT2 receptor antagonist haloperidol in combination with the dopamine (D) 2 receptor antagonist ritanserin was found to help alleviate both the negative and positive symptoms of the disease, with a concomitant reduction in adverse movement disorders [66].

    View all citing articles on Scopus
    View full text